Blog

SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be presenting today, Monday, November 3rd, at 09:45am ET at the Spartan Capital Investor Conference 2025 in New York City.

Event Information:

Event	NanoViricides Presentation at the Spartan Capital Investor Conference – 2025, New York, NY	Track	2
Date	Monday, November 3, 2025	Time	09:45am
Location	Marriott Marquis Hotel, New York, NY

Anil R. Diwan, PhD, President and Executive Chairman of the Company will provide an update on the Company, its Drug Pipeline and Platform Technologies available for licensing.

NanoViricides’ Current Antiviral Drugs Pipeline: NV-387, A Revolutionary Broad-Spectrum Antiviral with Multiple Indications

The Phase II clinical stage revolutionary broad antiviral spectrum of NV-387 is reminiscent of the dawn of antibiotics to combat bacterial infections. Over 90% of human pathogenic viruses use heparan sulfate features, which NV-387 copies and presents to fool the virus.

NV-387 is designed to attack the virus particle and destroy it by fooling the virus to enter the NV-387 nanomicelle using the same features that the virus uses to infect cells.

Viruses cannot escape NV-387 despite all the changes in the field because the virus still needs to bind to heparan-sulfate like features in order to cause productive pathogenic infection. NV-387 presents copious amounts of these binding sites to the virus, thereby engulfing the virus particle. Viruses are unlikely to escape NV-387 because no matter how much a virus evolves, it continues to utilize and require binding to sulfated proteoglycans – the very characteristic that NV-387 emulates.

This solves the long-standing problem of antiviral medicines, that viruses escape them. Vaccines, antibodies and small chemical drugs are readily escaped by viruses as the viruses evolve in the field. This has been repeatedly observed during the recent COVID-19 pandemic, as well as in the course of most of the other viral epidemics including Influenza and HIV/AIDS.

NV-387 stands to combat viral infections where there is no current medical treatment available, including RSV for pediatrics, Measles, MPox, and others.

NanoViricides lead clinical stage drug candidate NV-387 is rapidly moving into Phase II clinical trial for the treatment of MPox in the Democratic Republic of Congo.

Additionally, NV-387 was found to be substantially superior to Tamiflu as well as Xofluza against Influenza virus in animal model studies ^[1].

Should Bird Flu H5N1 turn into a human outbreak, variants resistance to Tamiflu and Xofluza can be expected to generate rapidly ^[2]. NV-387 would be the ideal drug to combat the resulting outbreak, epidemic or pandemic. The causative influenza virus would not be able to escape NV-387 ^[3].

A separate Phase II clinical trial for the evaluation of NV-387 as a first line therapy of any respiratory viral infection (NV-387 for the treatment of Viral Acute or Severe Acute respiratory Infections, Viral ARI/SARI) is being planned. Success in this clinical trial would enable NV-387 to become the first ever antiviral drug that can be prescribed by a physician based on symptoms, as an emperic therapy for respiratory viral infections, without having to test for which virus is causing the disease.

NV-387 would play in a market size of well over $20 Billion as a dominant player, if approved for such emperic therapy of viral ARI/SARI.

NV-387 was found to be highly effective against the “tripledemic” respiratory viruses, namely RSV, Influenza A, and Coronaviruses, in respective lethal animal models of lung infection. NV-387 was found to be substantially superior to existing drugs, and even resulted in complete cure in the RSV animal study. These studies prompted evaluation of NV-387 as a first line therapy of respiratory viral infections.

There is no treatment approved for RSV, an important disease for infants and children in early life, as well as for geriatric subjects.

NV-387 has shown excellent effectiveness in lethal lung infection animal models relevant for Smallpox and MPox viruses.

There is no treatment approved for MPox; tecovirimat (TPOXX) has failed clinical trials, and no results are available from the brincidofovir (TEMBEXA) clinical trial “MOSA”.

“For Smallpox bio-threat readiness, the USA remains without an effective drug because of deficiencies in the two drugs approved under animal rule ^[4],” asserted Anil Diwan, PhD, President of the Company, adding, “NV-387 is ready to fill this gap.”

US government acquisitions for smallpox drugs have been in the range of hundreds of millions of dollars.

Additionally, NV-387 has shown excellent effectiveness against Measles virus lethal lung infection in a humanized (hCD150+ knock-in) mouse model.

There is no treatment approved for Measles. Cases of Measles have been rapidly rising in the developing world including USA, Canada, UK and European countries. Measles is an important health threat because the disease can lead to “immune amnesia”, wiping out pre-developed immunity against other diseases, because it attacks the immune system itself.

NanoViricides’ Robust Technology Platform Has Enabled a Broad Drugs Pipeline: HerpesViruses, HIV, Others

The nanoviricides™ platform technology is yielding novel antiviral drug candidates against a number of challenging viral targets at a rapid pace.

In addition to NV-387, the Company has developed a clinical-ready pan-herpesvirus drug candidate, NV-HHV-1 that has shown activity against HSV-1, HSV-2 and VZV, and is expected to have activity against CMV, HHV-6, and HHV-8 as well.

The Company has also developed an anti-HIV drug candidate, NV-HIV-1, that has shown strong efficacy in SCID-hu-Thy-Liv animal model of HIV infection. NV-HHV-1 mimics the landing site on cellular CD4 that is required for all HIV viruses to cause cellular infection. Thus, HIV, despite constant changes, will be unable to escape NV-HHV-1.

NanoViricide Platform Enables Drug Rescue, Oral Drug Delivery, and Zip-Code Specific Delivery

Oral drug delivery of small chemicals, peptides (such as the GLP-a obesity drugs), and proteins is feasible by encapsulation of the guest drug into the nanoviricide polymeric micelle. The encapsulation protects the guest from metabolism thereby enabling effective drug delivery.

Encapsulation of a difficult or failed drug within the nanoviricide polymeric micelle can enable rescue of the drug candidate turning it into a clinically viable drug candidate, saving hundreds of millions of dollars of development work.

Going another step further, the nanoviricide platform technology can be customized to enable zip-code-like specific delivery of encapsulated drugs to specific tissues (e.g. non-liver targeted delivery),, cells (e.g. cancer-cell specific delivery sparing normal cells), bacteria, or viruses (e.g. NV-HHV-1, NV-HIV-1) in a fully synthetic chemistry based, scalable technology stack.

ABOUT THE SPARTAN CAPITAL INVESTOR CONFERENCE 2025

The Spartan Capital Investor Conference is a premier event that brings together public company executive teams, institutional investors, thought leaders in the U.S. capital markets, and representatives from Spartan Capital. This conference offers a unique opportunity for networking, knowledge sharing, and strategic discussions.

ABOUT NANOVIRICIDES

NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
ir@nanoviricides.com

View the original press release on ACCESS Newswire

Samples collected for fine grinding testwork, mine design & costing

ADELAIDE, AU / ACCESS Newswire / November 3, 2025 / Barton Gold Holdings Limited (ASX:BGD)(OTCQB:BGDFF)(FRA:BGD3) (Barton or the Company) has completed TSF1 geotechnical drilling in support of a recently launched Definitive Feasibility Study for ‘Stage 1′ production (Stage 1 DFS) at the Company’s South Australian Challenger Gold Project (Challenger). ¹

The program included 5 sonic drill holes to recover TSF1 materials for lab testing, 24 holes for Cone Penetration Testing ( CPTu ) and further laboratory testing, and 3 holes each for vein shear testing (VST) and bulk density (BD) testing. Results will inform TSF1 detailed mine design, equipment selection, and operating cost estimates.

Figure 1 – TSF1 with completed CPT (red), sonic (green stars), VST / BD (orange) & AC / RC drill holes

Commenting on the TSF1 geotechnical drilling, Barton Managing Director Alexander Scanlon said:

“This drilling is the first of several production-related work programs completed for our ‘Stage 1′ production DFS at the Central Gawler Mill. The samples collected will be used for fine grinding testwork, and to inform key elements of mine design, equipment selection and operating costs for tailings recovery and processing.”

Authorised by the Managing Director of Barton Gold Holdings Limited.

For further information, please contact:

Alexander Scanlon Managing Director a.scanlon@bartongold.com.au +61 425 226 649

Jade Cook Company Secretary cosec@bartongold.com.au +61 8 9322 1587

About Barton Gold

Barton Gold is an ASX, OTCQB and Frankfurt Stock Exchange listed Australian gold developer targeting future gold production of 150,000ozpa with 2.2Moz Au & 3.1Moz Ag JORC Mineral Resources (79.9Mt @ 0.87g/t Au), brownfield mines, and 100% ownership of the region’s only gold mill in the renowned Gawler Craton of South Australia. ^*

Challenger Gold Project 313koz Au + fully permitted Central Gawler Mill ( CGM ) Tarcoola Gold Project 20koz Au in fully permitted open pit mine near CGM Tolmer discovery grades up to 84g/t Au & 17,600g/t Ag Tunkillia Gold Project 1.6Moz Au & 3.1Moz Ag JORC Mineral Resources Competitive 120kozpa gold & 250kozpa silver project Wudinna Gold Project 279koz Au project located southeast of Tunkillia Significant optionality, adjacent to main highway

Competent Persons Statement & Previously Reported Information

The information in this announcement that relates to the historic Exploration Results and Mineral Resources as listed in the table below is based on, and fairly represents, information and supporting documentation prepared by the Competent Person whose name appears in the same row, who is an employee of or independent consultant to the Company and is a Member or Fellow of the Australasian Institute of Mining and Metallurgy (AusIMM), Australian Institute of Geoscientists (AIG) or a Recognised Professional Organisation (RPO). Each person named in the table below has sufficient experience which is relevant to the style of mineralisation and types of deposits under consideration and to the activity which he has undertaken to quality as a Competent Person as defined in the JORC Code 2012 ( JORC ).

Activity	Competent Person	Membership	Status
Tarcoola Mineral Resource (Stockpiles)	Dr Andrew Fowler (Consultant)	AusIMM	Member
Tarcoola Mineral Resource (Perseverance Mine)	Mr Ian Taylor (Consultant)	AusIMM	Fellow
Tarcoola Exploration Results (until 15 Nov 2021)	Mr Colin Skidmore (Consultant)	AIG	Member
Tarcoola Exploration Results (after 15 Nov 2021)	Mr Marc Twining (Employee)	AusIMM	Member
Tunkillia Exploration Results (until 15 Nov 2021)	Mr Colin Skidmore (Consultant)	AIG	Member
Tunkillia Exploration Results (after 15 Nov 2021)	Mr Marc Twining (Employee)	AusIMM	Member
Tunkillia Mineral Resource	Mr Ian Taylor (Consultant)	AusIMM	Fellow
Challenger Mineral Resource (above 215mRL)	Mr Ian Taylor (Consultant)	AusIMM	Fellow
Challenger Mineral Resource (below 90mRL)	Mr Dale Sims	AusIMM / AIG	Fellow / Member
Wudinna Mineral Resource (Clarke Deposit)	Ms Justine Tracey	AusIMM	Member
Wudinna Mineral Resource (all other Deposits)	Mrs Christine Standing	AusIMM / AIG	Member / Member

The information relating to historic Exploration Results and Mineral Resources in this announcement is extracted from the Company’s Prospectus dated 14 May 2021 or as otherwise noted, available from the Company’s website at www.bartongold.com.au or on the ASX website www.asx.com.au. The Company confirms that it is not aware of any new information or data that materially affects the Exploration Results and Mineral Resource information included in previous announcements and, in the case of estimates of Mineral Resources, that all material assumptions and technical parameters underpinning the estimates, and any production targets and forecast financial information derived from the production targets, continue to apply and have not materially changed. In accordance with ASX Listing Rule 5.19.2, the Company further confirms that the material assumptions underpinning any production targets and the forecast financial information derived therefrom continue to apply and have not materially changed. The Company confirms that the form and context in which the applicable Competent Persons’ findings are presented have not been materially modified from the previous announcements.

Cautionary Statement Regarding Forward-Looking Information

This document may contain forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “expect”, “target” and “intend” and statements than an event or result “may”, “will”, “should”, “would”, “could”, or “might” occur or be achieved and other similar expressions. Forward-looking information is subject to business, legal and economic risks and uncertainties and other factors that could cause actual results to differ materially from those contained in forward-looking statements. Such factors include, among other things, risks relating to property interests, the global economic climate, commodity prices, sovereign and legal risks, and environmental risks. Forward-looking statements are based upon estimates and opinions at the date the statements are made. Barton undertakes no obligation to update these forward-looking statements for events or circumstances that occur subsequent to such dates or to update or keep current any of the information contained herein. Any estimates or projections as to events that may occur in the future (including projections of revenue, expense, net income and performance) are based upon the best judgment of Barton from information available as of the date of this document. There is no guarantee that any of these estimates or projections will be achieved. Actual results will vary from the projections and such variations may be material. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. Any reliance placed by the reader on this document, or on any forward-looking statement contained in or referred to in this document will be solely at the readers own risk, and readers are cautioned not to place undue reliance on forward-looking statements due to the inherent uncertainty thereof.

¹ Refer to ASX announcements dated 29 September and 23 October 2025

^* Refer to Barton Prospectus dated 14 May 2021 and ASX announcement dated 8 September 2025. Total Barton JORC (2012) Mineral Resources include 1,049koz Au (39.7Mt @ 0.82 g/t Au) in Indicated category and 1,186koz Au (40.2Mt @ 0.92 g/t Au) in Inferred category, and 3,070koz Ag (34.5Mt @ 2.80 g/t Ag) in Inferred category as a subset of Tunkillia gold JORC (2012) Mineral Resources.

SOURCE: Barton Gold Holdings Limited

View the original press release on ACCESS Newswire

Designed for business owners and accountants juggling multiple deadlines, Auto Payroll handles recurring pay runs automatically, accurately, and on schedule.

CANTON, OH / ACCESS Newswire / November 4, 2025 / Patriot Software, a leading provider of accounting and payroll software in the USA, today announced Auto Payroll, a powerful new feature designed to eliminate repetitive administrative work for small business owners and accountants. The feature is available immediately to both Full Service Payroll and Basic Payroll customers.

Auto Payroll is engineered for companies with predictable payrolls, where employees and pay amounts remain consistent each run. By fully automating these recurring pay runs, Patriot empowers business owners to eliminate tedious re-entry and oversight tasks, saving time, reducing human error, and keeping operations running effortlessly.

Payroll is essential, yet it consistently ranks as one of the biggest time drains for small business owners. A recent survey found that owners spend an average of five hours every single pay period preparing and processing payroll. Although customers already average minutes with Patriot Payroll^®, Auto Payroll eliminates the need to log in entirely, saving business owners with routine, unchanging payrolls even more precious time.

“This feature saves employers valuable time,” said Mary Rolfes, Payroll Product Manager at Patriot Software. “Our customers already appreciate how simple payroll is with Patriot. Auto Payroll takes that simplicity a step further, eliminating extra steps for those who pay the same employees the same amount each period. It’s designed for busy owners and accountants who need to streamline their work without sacrificing accuracy.”

Built with flexibility and precision at its core, Auto Payroll supports both salaried and hourly employees, with or without direct deposit. Crucially, employers still receive an advance notification before each scheduled run is processed, providing a final window of time to easily stop the payroll if needed before the system executes the run.

American business owners wanting to take advantage of Patriot Software’s automated payroll as well as other time saving features, can sign up on Patriot’s website, www.patriotsoftware.com, for a 30-day free trial. Following the trial, new customers can enjoy 50% off for the next three months.

Patriot Software is disrupting the accounting and payroll industries with its low prices, achieving the 100th percentile for customer loyalty and satisfaction, and award-winning software. Patriot offers cloud-based accounting, payroll, HR, and time and attendance software solutions that help American businesses with up to 500 employees simplify their administrative tasks. Patriot’s US-based customer support team provides a personal touch that most software companies lack today. The company has been serving tens of thousands of businesses nationwide since 2002.

For more information, please contact:

Rachel Gray
Content Manager
marketing@patriotsoftware.com
877-968-7147

SOURCE: Patriot Software, LLC

View the original press release on ACCESS Newswire

Lee’s Famous Recipe Chicken Strengthens Supply Chain Operations with ArrowStream

CHICAGO, IL / ACCESS Newswire / November 4, 2025 / ArrowStream, Inc. (“ArrowStream”), the leading provider of end-to-end supply chain management software for the foodservice industry, announced today Lee’s Famous Recipe® Chicken (“Lee’s”), a name synonymous with delicious, home-style fried chicken, has renewed its partnership with ArrowStream to continue modernizing its supply chain performance and operational efficiency.

For nearly 60 years, Lee’s has been famous for its hand-breaded chicken that is prepared fresh daily. Starting as a single store in Lima, Ohio, Lee’s has grown across the United States and Canada to over 130 locations. With ambitious growth plans in the coming years, Lee’s continues to be supported by ArrowStream Central, a platform designed specifically for restaurant operators to streamline operations, reduce costs, and improve efficiency.

With ArrowStream Central, Lee’s gains real-time visibility into its purchasing and distribution data, allowing its team to quickly identify issues, analyze spend, and uncover savings opportunities. The platform also enables Lee’s to manage supplier compliance, ensure accurate pricing, and maintain product consistency across all restaurant locations.

“ArrowStream has become an essential part of how we manage our business,” said Ryan Weaver, CEO at Lee’s Famous Recipe Chicken. “We operate a lean team, but because ArrowStream’s platform is so intuitive and easy to use, we’re able to fully leverage everything it offers. It’s a robust solution that gives us the visibility, control, and insights we need to make confident decisions, keep our supply chain efficient, and support our restaurants as we continue to grow.”

By centralizing data and improving communication across its network, ArrowStream helps Lee’s proactively address supply disruptions, quickly resolve product quality and service incidents through Foodservice Incident Management (FSIM), and stay ahead of market shifts. This partnership ensures the brand can maintain high-quality standards, resolve issues efficiently, and deliver a consistent guest experience, even as supply chain demands evolve.

“We are proud to continue supporting Lee’s Famous Recipe Chicken,” said Jay Moon, Chief Customer Officer at ArrowStream. “Our goal is to help operators like Lee’s simplify the complexity of supply chain management through better data, stronger partnerships, and smarter decision-making. Lee’s success demonstrates how technology and collaboration can work together to drive performance across the entire supply chain.”

Lee’s is part of a growing group of restaurant brands using ArrowStream to optimize sourcing, maintain quality compliance, and manage costs more effectively. From large national franchises to emerging regional chains, ArrowStream provides foodservice operators with the tools and insights needed to stay competitive in a fast-changing industry. That is why brands like IPC Subway, Topgolf, and Noodles & Company trust ArrowStream to elevate their supply chain.

For restaurant chains interested in improving visibility and control within their supply chain, reach out to a supply chain expert at ArrowStream to learn more.

Contact Information

Joe Ferrell
VP, Marketing – SaaS Division
joe.ferrell@buyersedgeplatform.com

SOURCE: ArrowStream

View the original press release on ACCESS Newswire

BOISBRIAND, QUEBEC / ACCESS Newswire / November 4, 2025 / Vision Marine Technologies Inc. (NASDAQ:VMAR) (“Vision Marine” or the “Company”), a company specializing in high-voltage marine propulsion, together with its recently acquired retail network Nautical Ventures, an award-winning Florida-based dealership group with eight locations, today announced the filing of a new patent application, VM1015US01, with the United States Patent and Trademark Office.

The Company’s 13th patent filing introduces an intelligent cooling-inlet assembly located on the electric outboard of Vision Marine’s E-Motion™ 180E high-voltage electric marine powertrain, designed to enhance efficiency, reliability, and ease of maintenance for electric boat users. This development reinforces Vision Marine’s growing portfolio of proprietary technologies and supports its strategy to integrate innovation with scalable retail and service operations.

The newly patented system incorporates a sealed cooling-inlet assembly positioned directly on the electric outboard, providing a connection fitting that feeds the electric water pump mounted under the cowling. This configuration supports improved thermal management and ease of access for maintenance.

This innovation allows the motor to maintain optimal performance in all conditions while offering a quieter and smoother ride. It also reduces service requirements and extends the lifespan of propulsion components, directly improving reliability and peace of mind for E-Motion™-equipped boat owners.

“The innovation enables cooling performance that adapts intelligently to the motor’s temperature and usage,” said Daniel Rathe, Chief Technology Officer at Vision Marine Technologies. “It also makes service more convenient. The pump and impeller can be accessed directly under the cowling and serviced with the boat in the water without removing the lower unit, which significantly improves the ownership experience.”

By relocating the cooling components and allowing the electric water pump to operate independently, the system enables flushing without engaging the propulsion motor. This simplifies maintenance and enhances durability. It also provides helm notifications if cooling flow becomes restricted or irregular, giving users clear feedback and protecting the powertrain.

“This innovation highlights our engineering team’s ability to translate real-world user needs into practical design improvements,” said Maxime Poudrier, Chief Operating Officer at Vision Marine Technologies. “It represents another example of how we continue to refine the E-Motion™ 180E platform for long-term performance and ease of use.”

This new patent follows a series of technology developments that support Vision Marine’s E-Motion™ platform and its broader commercialization strategy through Nautical Ventures, its U.S. distribution and service network. Nautical Ventures continues to play a key role in demonstrating and servicing Vision Marine’s high-voltage electric propulsion systems while introducing new consumers to the benefits of electric boating.

With 13 patents now filed and additional integrations underway with global boat manufacturers, Vision Marine continues to strengthen its position as a marine technology company backed by a scalable retail and service foundation. The Company’s vertically integrated structure combines engineering innovation with direct consumer access, providing a complete platform for the future of performance boating.

This patent reinforces Vision Marine’s ability to deliver proprietary technology specifically engineered for the marine environment, strengthening the Company’s long-term competitive advantage in electric propulsion. Each new patent expands the foundation for future OEM partnerships and licensing opportunities while deepening Vision Marine’s integration capabilities across its own retail network, Nautical Ventures. Together, these assets position Vision Marine to capture a growing share of the accelerating transition toward high-performance electric boating solutions.

About Vision Marine Technologies Inc.

Vision Marine Technologies Inc. (NASDAQ:VMAR) is a marine technology company transforming the boating experience through innovation in both electric and internal-combustion propulsion. Vision Marine designs, manufactures, and integrates high-voltage electric powertrain systems and performance boats, while operating a vertically integrated retail and service network through its subsidiary, Nautical Ventures, one of the top dealership groups in the United States.

Together, Vision Marine and Nautical Ventures form North America’s first fully integrated technology and retail platform, bringing consumers and manufacturers the next generation of on-water experiences.

For more information, visit www.visionmarinetechnologies.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially. Vision Marine Technologies undertakes no obligation to update these statements except as required by law.

Investor Relations
Bruce Nurse
Vision Marine Technologies Inc.
Email: bn@v-mti.com
Phone: (303) 919-2913

SOURCE: Vision Marine Technologies Inc

View the original press release on ACCESS Newswire

New brand identity underscores MustardSeed’s evolution into a multi-sector project management partner delivering clarity, precision, and measurable results.

PHILADELPHIA, PA / ACCESS Newswire / November 4, 2025 / MustardSeed, a leading project management and strategy consultancy, today announced the launch of its refreshed brand identity, signaling the company’s rapid growth and expansion into new industries. Originally established with a strong foundation in life sciences, MustardSeed has broadened its reach into additional high-impact sectors including food, integrated systems, and aerospace & defense.

Over the last two years, MustardSeed has tripled the size of its team to meet growing client demand. The updated brand identity features a modernized logo and visual system that represents this evolution and underscores the company’s continued commitment to helping organizations execute with clarity, precision, and measurable impact.

“MustardSeed’s growth has been fueled by our clients’ trust and the dedication of our team,” said Steve Curry, CEO of MustardSeed. “As we continue to expand into new industries, our refreshed brand identity reflects not just who we are today but also where we are heading. We are excited about the future and the opportunity to deliver value at scale for our partners.”

The new identity builds on MustardSeed’s reputation for bringing fresh thinking to project management in industries where precision and performance are critical. By aligning strategy with execution, MustardSeed enables organizations to unlock efficiency, reduce risk, and accelerate growth.

For more information, visit www.mustardseedpmo.com.

About MustardSeed

MustardSeed is a project management and strategy consultancy that partners with organizations to deliver projects that matter. From foundational planning to strategic execution, MustardSeed helps clients break through complexity, align teams, and achieve lasting results across sectors including life sciences, food, integrated systems, and aerospace & defense.

SOURCE: MustardSeed PMO – Because Execution Matters

View the original press release on ACCESS Newswire

Please note that the limited information that follows in this press release is not adequate to make an informed investment judgment.

MCLEAN, VA / ACCESS Newswire / November 3, 2025 / Gladstone Commercial Corporation (Nasdaq:GOOD) (“Gladstone Commercial” or the “Company”) today reported financial results for the third quarter ended September 30, 2025. A description of funds from operations, or FFO, and Core FFO, both non-GAAP (generally accepted accounting principles in the United States) financial measures, are located at the end of this press release. All per share references are to fully-diluted weighted average shares of common stock and Non-controlling OP Units, unless otherwise noted. For further detail, please also refer to both the quarterly financial supplement and the Company’s Quarterly Report on Form 10-Q, which can be retrieved from the Investors section of our website at www.gladstonecommercial.com.

Summary Information (dollars in thousands, except share and per share data):

		As of and for the three months ended
		September 30, 2025					June 30, 2025					$ Change				% Change
Operating Data:
Total operating revenue		$	40,841				$	39,533				$	1,308				3.3	%
Total operating expenses			(26,021	)				(25,146	)	(2)			(875	)			3.5	%
Other expense, net			(10,683	)	(1)			(9,753	)	(3)			(930	)			9.5	%
Net income		$	4,137				$	4,634				$	(497	)			(10.7	)%
Less: Dividends attributable to preferred stock			(3,058	)				(3,085	)				27				(0.9	)%
Less: Dividends attributable to senior common stock			(102	)				(101	)				(1	)			1.0	%
Add: Gain on extinguishment of Series F preferred stock, net			6					9					(3	)			(33.3	)%
Net income available to common stockholders and Non-controlling OP Unitholders		$	983				$	1,457				$	(474	)			(32.5	)%
Add: Real estate depreciation and amortization			15,271					14,249					1,022				7.2	%
Add: Impairment charge			–					9					(9	)			(100.0	)%
Add: Loss on sale of real estate, net			10					–					10				100.0	%
Less: Gain on sale of real estate, net			–					(377	)				377				(100.0	)%
Funds from operations available to common stockholders and Non-controlling OP Unitholders – basic		$	16,264				$	15,338				$	926				6.0	%
Add: Convertible senior common distributions			102					101					1				1.0	%
Funds from operations available to common stockholders and Non-controlling OP Unitholders – diluted		$	16,366				$	15,439				$	927				6.0	%
Funds from operations available to common stockholders and Non-controlling OP Unitholders – basic		$	16,264				$	15,338				$	926				6.0	%
Add: Write off prepaid offering costs			–					305					(305	)			(100.0	)%
Add: Asset retirement obligation expense			34					34					–				–	%
Add: Closing costs on sale			–					336					(336	)			(100.0	)%
Core funds from operations available to common stockholders and Non-controlling OP Unitholders – basic		$	16,298				$	16,013				$	285				1.8	%
Add: Convertible senior common distributions			102					101					1				1.0	%
Core funds from operations available to common stockholders and Non-controlling OP Unitholders – diluted		$	16,400				$	16,114				$	286				1.8	%
Share and Per Share Data:
Net income available to common stockholders and Non-controlling OP Unitholders – basic and diluted		$	0.02				$	0.03				$	(0.01	)			(33.3	)%
FFO available to common stockholders and Non-controlling OP Unitholders – basic		$	0.35				$	0.33				$	0.02				6.1	%
FFO available to common stockholders and Non-controlling OP Unitholders – diluted		$	0.35				$	0.33				$	0.02				6.1	%
Core FFO available to common stockholders and Non-controlling OP Unitholders – basic		$	0.35				$	0.35				$	–				–	%
Core FFO available to common stockholders and Non-controlling OP Unitholders – diluted		$	0.35				$	0.35				$	–				–	%
Weighted average shares of common stock and Non-controlling OP Units outstanding – basic			46,917,160					46,259,137					658,023				1.4	%
Weighted average shares of common stock and Non-controlling OP Units outstanding – diluted			47,245,719					46,587,696					658,023				1.4	%
Cash dividends declared per common share and Non-controlling OP Unit		$	0.30				$	0.30				$	–				–	%
Financial Position
Real estate, before accumulated depreciation		$	1,400,357				$	1,350,523		(4)		$	49,834				3.7	%
Total assets		$	1,265,003				$	1,209,993				$	55,010				4.5	%
Mortgage notes payable, net, borrowings under revolver, borrowings under term loan, net, borrowings under unsecured term loan, net, and senior unsecured notes, net		$	843,285				$	794,391				$	48,894				6.2	%
Total equity and mezzanine equity		$	354,999				$	347,362				$	7,637				2.2	%
Properties owned			151					143		(4)			8				5.6	%
Square feet owned			17,675,963					17,038,727		(4)			637,236				3.7	%
Square feet leased			99.1	%				98.7	%				0.4	%			0.4	%

(1)		Includes a $0.01 million loss on sale, net, from the sale of one property during the three months ended September 30, 2025.
(2)		Includes a $0.01 million impairment charge recognized on one property during the three months ended June 30, 2025.
(3)		Includes a $0.4 million gain on sale, net, from the sale of one property during the three months ended June 30, 2025.
(4)		Includes one property classified as held for sale of $3.4 million and 56,000 square feet.

Third Quarter Activity:

• Collected 100% of cash rents: Collected 100% of cash rents due during July, August, and September;

• Acquired properties: Purchased a fully-occupied, six-facility portfolio, with an aggregate of 693,236 square feet of rental space, for $54.8 million, at a weighted average cap rate of 9.53%;

• Sold properties: Sold one non-core industrial property as part of our capital recycling strategy for $3.0 million;

• Completed leasing activity: Completed leasing activity on 734,464 square feet of property with remaining lease terms ranging from 0.7 years to 11.4 years at 14 of our properties;

• Issued common stock under ATM Program: Issued 1,891,807 shares of common stock under our at-the-market (“ATM”) program for net proceeds of $23.0 million; and

• Paid distributions: Paid monthly cash distributions for the quarter totaling $0.30 per share on our common stock and Non-controlling OP Units, $0.414063 per share on our Series E Preferred Stock, $0.375 per share on our Series F Preferred Stock, $0.375 per share on our Series G Preferred Stock, and $0.2625 per share on our senior common stock.

Third Quarter 2025 Results: Core FFO available to common shareholders and Non-controlling OP Unitholders for the three months ended September 30, 2025 was $16.4 million, a 1.8% increase when compared to the three months ended June 30, 2025, equaling $0.35 per share. Core FFO increased primarily due to higher revenues from year to date acquisitions and leasing activity, partially offset by an increase in interest expense from higher outstanding variable rate debt and higher general and administrative expenses.

Net income available to common stockholders and Non-controlling OP Unitholders for the three months ended September 30, 2025 was $1.0 million, or $0.02 per share, compared to net income available to common stockholders and Non-controlling OP Unitholders for the three months ended June 30, 2025 of $1.5 million, or $0.03 per share. In the Summary Information table above, we provide a reconciliation of Core FFO to net income (which we believe is the most directly comparable GAAP measure to Core FFO) for the three months ended September 30, 2025 and June 30, 2025, a computation of basic and diluted Core FFO per weighted average share of common stock and Non-controlling OP Unit, and basic and diluted net income per weighted average share of common stock and Non-controlling OP Unit.

Subsequent to the end of the quarter:

• Collected 100% of October cash rents: Collected 100% of cash rents due in October;

• Amended, extended, and upsized credit facility: Increased our revolver from $155.0 million to $200.0 million and increased our aggregate term loan component from $350.0 million to $400.0 million. The revolver maturity was extended to October 2029 and Term Loan A and Term Loan B components maturity were extended to October 2029 and February 2030, respectively. In total, the credit facility increased to $600.0 million;

• Repaid debt: Repaid $3.1 million in fixed rate mortgage debt at an interest rate of 4.59%; and

• Declared distributions: Declared monthly cash distributions for October, November, and December 2025, totaling $0.30 per share on our common stock and Non-controlling OP Units, $0.414063 per share on our Series E Preferred Stock, $0.375 per share on our Series F Preferred Stock, $0.375 per share on our Series G Preferred Stock, and $0.2625 per share on our senior common stock.

Comments from Gladstone Commercial’s President, Buzz Cooper: “Our financial results reflect consistent performance and stabilized revenues from our tremendous same store property occupancy, rent collection and growth, accretive real estate investments made during 2024 and 2025, and our ability to renew tenants. We have continued our capital recycling program, whereby we have sold non-core assets and used the proceeds to de-lever our portfolio, as well as to acquire properties in our target growth markets. We have successfully exited two non-core assets thus far in 2025, and we have additional non-core assets we anticipate selling over the next one to two years. We will continue to opportunistically sell non-core assets and redeploy the proceeds into stronger target growth markets with a focus on industrial investment opportunities. While we expect to face challenges due to the lingering effects of the pandemic, inflation with corresponding high interest rates, and the geo-political and economic issues arising from international wars, we feel strongly about the depth of our tenant credit underwriting. We have collected 100% of the first three quarters’ cash rents and 100% of October cash rents. We anticipate our tenants will successfully navigate the current economic climate and will be able to continue operating successfully when economic normalcy returns fully. Despite economic uncertainty, so far during 2025, we completed leasing activity on 857,481 square feet of property with 12 tenants. We are actively marketing our remaining vacant space and currently anticipate positive outcomes. We expect to continue to have access to the debt and equity markets, as necessary, for added liquidity. We believe our same store rents, which have increased by 2% annually in recent years, should continue to rise as we grow, and we will continue to primarily focus on investing in our target markets, with an emphasis on industrial properties and actively managing our portfolio.”

Conference Call: Gladstone Commercial will hold a conference call on Tuesday, November 4, 2025, at 8:30 a.m. Eastern Time to discuss its earnings results. Please call (877) 407-9045 to enter the conference call. An operator will monitor the call and set a queue for questions. A conference call replay will be available beginning one hour after the call and will be accessible through November 11, 2025. To hear the replay, please dial (877) 660-6853 and use playback conference number 13755539. The live audio broadcast of the Company’s quarterly conference call will also be available on the investors section of our website, www.gladstonecommercial.com.

About Gladstone Commercial: Gladstone Commercial Corporation is a real estate investment trust focused on acquiring, owning, and operating net leased industrial and office properties across the United States. Further information can be found at www.gladstonecommercial.com.

About the Gladstone Companies: Information on the business activities of the Gladstone family of funds can be found at www.gladstonecompanies.com.

Investor Relations: For Investor Relations inquiries related to any of the monthly distribution-paying Gladstone family of funds, please visit www.gladstonecompanies.com.

Non-GAAP Financial Measures:

FFO: The National Association of Real Estate Investment Trusts (“NAREIT”) developed FFO as a relative non-GAAP supplemental measure of operating performance of an equity REIT to recognize that income-producing real estate historically has not depreciated on the basis determined under GAAP. FFO, as defined by NAREIT, is net income (computed in accordance with GAAP), excluding gains (or losses) from sales of property and impairment losses on property, plus depreciation and amortization of real estate assets, and after adjustments for unconsolidated partnerships and joint ventures. FFO does not represent cash flows from operating activities determined in accordance with GAAP and should not be considered an alternative to net income as an indication of its performance or to cash flow from operations as a measure of liquidity or ability to make distributions. The Company believes that FFO per share provides investors with an additional context for evaluating its financial performance and as a supplemental measure to compare it to other REITs; however, comparisons of its FFO to the FFO of other REITs may not necessarily be meaningful due to potential differences in the application of the NAREIT definition used by such other REITs.

Core FFO: Core FFO is FFO adjusted for certain items that are not indicative of the results provided by the Company’s operating portfolio and affect the comparability of the Company’s period-over-period performance. These items include the adjustment for acquisition related expenses, gains or losses from early extinguishment of debt and any other non-recurring expense adjustments. Although the Company’s calculation of Core FFO differs from NAREIT’s definition of FFO and may not be comparable to that of other REITs, the Company believes it is a meaningful supplemental measure of its operating performance. Accordingly, Core FFO should be considered a supplement to net income computed in accordance with GAAP as a measure of our performance.

The Company’s presentation of FFO, as defined by NAREIT, or presentation of Core FFO, does not represent cash flows from operating activities determined in accordance with GAAP and should not be considered an alternative to net income as an indication of its performance or to cash flow from operations as a measure of liquidity or ability to make distributions.

The statements in this press release regarding the forecasted stability of Gladstone Commercial’s income, its ability, plans or prospects to re-lease its unoccupied properties, and grow its portfolio are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements inherently involve certain risks and uncertainties, although they are based on Gladstone Commercial’s current plans that are believed to be reasonable as of the date of this press release. Factors that may cause actual results to differ materially from these forward-looking statementsinclude, but are not limited to, Gladstone Commercial’s ability to raise additional capital; availability and terms of capital and financing, both to fund its operations and to refinance its indebtedness as it matures; downturns in the current economic environment; the performance of its tenants; the impact of competition on its efforts to renew existing leases or re-lease space; and significant changes in interest rates.Additional factors that could cause actual results to differ materially from those stated or implied by its forward-looking statements are disclosed under the caption “Risk Factors” of its Form 10-K for the fiscal year ended December 31, 2024, as filed with the SEC on February 18, 2025, and other reports filed with the SEC.Gladstone Commercial cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made.Gladstone Commercial undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

CONTACT:

Gladstone Commercial Corporation
(703) 287-5893

SOURCE: Gladstone Commercial Corporation

View the original press release on ACCESS Newswire